C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients

Elisa Kankkunen; Patrick Penttilä; Katriina Peltola; Petri Bono

doi:10.1080/0284186X.2022.2104132

C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients

Elisa Kankkunen, Patrick Penttilä, Katriina Peltola, Petri Bono

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Tidskrift	Acta Oncologica
Volym	61
Nummer	10
Sidor (från-till)	1240-1247
Antal sidor	8
ISSN	0284-186X
DOI	https://doi.org/10.1080/0284186X.2022.2104132
Status	Publicerad - 3 okt. 2022
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

3122 Cancersjukdomar

Åtkomst av dokument

10.1080/0284186X.2022.2104132

Citera det här

@article{273c9234b7d84334a29b9cc86819a9fb,

title = "C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients",

keywords = "Nivolumab, C-reactive protein, immune-related adverse event, biomarker, metastatic renal cell carcinoma, TO-LYMPHOCYTE RATIO, NIVOLUMAB, CANCER, ASSOCIATION, SURVIVAL, Metastatic renal cell carcinoma, Biomarker, Immune-related adverse event, 3122 Cancers",

author = "Elisa Kankkunen and Patrick Penttil{\"a} and Katriina Peltola and Petri Bono",

year = "2022",

month = oct,

day = "3",

doi = "10.1080/0284186X.2022.2104132",

language = "English",

volume = "61",

pages = "1240--1247",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Taylor & Francis",

number = "10",

}

TY - JOUR

T1 - C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients

AU - Kankkunen, Elisa

AU - Penttilä, Patrick

AU - Peltola, Katriina

AU - Bono, Petri

PY - 2022/10/3

Y1 - 2022/10/3

KW - Nivolumab

KW - C-reactive protein

KW - immune-related adverse event

KW - biomarker

KW - metastatic renal cell carcinoma

KW - TO-LYMPHOCYTE RATIO

KW - NIVOLUMAB

KW - CANCER

KW - ASSOCIATION

KW - SURVIVAL

KW - Metastatic renal cell carcinoma

KW - Biomarker

KW - Immune-related adverse event

KW - 3122 Cancers

U2 - 10.1080/0284186X.2022.2104132

DO - 10.1080/0284186X.2022.2104132

M3 - Article

VL - 61

SP - 1240

EP - 1247

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 10

ER -